United States securities and exchange commission logo





                            January 29, 2021

       Senthil Sundaram
       Chief Executive Officer
       Terns Pharmaceuticals, Inc.
       1065 East Hillsdale Blvd., Suite 100
       Foster City, California 94404

                                                        Re: Terns
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed January 15,
2021
                                                            File No. 333-252180

       Dear Mr. Sundaram:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Form S-1 filed January 15, 2021

       Management's Discussion and Analysis of Financial Condition and Results
of Operations
       Critical accounting policies and significant judgments and estimates
       Common stock valuation methodology, page 105

   1.                                                   In your response dated
January 26, 2021, you noted that in October 2020 you reassessed
                                                        the grant date fair
value of all your grants made during the nine month period ended
                                                        September 30, 2020.
Your response does not address how you assessed the impact of the
                                                        revaluation on your
previously issued financial statements. If true, please revise your
                                                        disclosure to confirm
that you determined that the incremental stock compensation
                                                        applicable to the
historical quarterly periods was immaterial to those respective
                                                        periods. In addition,
revise your disclosure to quantify the aggregate number of options
                                                        granted that were
impacted by the retrospective valuation of your common stock as of
 Senthil Sundaram
Terns Pharmaceuticals, Inc.
January 29, 2021
Page 2
      September 1, 2020, the aggregate stock compensation to be recorded in the
three month
      period ended December 31, 2020, and the incremental additional stock
compensation
      expense that will be recorded in the three month period ended December
31, 2020 as a
      result of this retrospective valuation.
Notes to Unaudited Condensed Consolidated Financial Statements
14. Subsequent Events, page F-57

2.    We note that the December 2020 option grant appears to be included in
disclosure
      provided in Item 15. Recent Sales of Unregistered Securities: Equity
Plan-Related
      Issuances on page II-2. Further, you state in your response dated January
26, 2021 that
      you anticipate using the initial public offering price as the grant date
fair value for your
      grant of options in December 2020. Please revise Note 14 to disclose all
of the relevant
      information regarding your grant of options in December 2020, including
how you intend
      to value these options.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact David Burton at 202-551-3626 or Sasha Parikh at
202-551-3627 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Chris Edwards at 202-551-6761 or Celeste Murphy at 202-551-3257 with
any other
questions.



                                                            Sincerely,
FirstName LastNameSenthil Sundaram
                                                            Division of
Corporation Finance
Comapany NameTerns Pharmaceuticals, Inc.
                                                            Office of Life
Sciences
January 29, 2021 Page 2
cc:       Brian Cuneo
FirstName LastName